13D Filing: Great Point Partners and Bovie Medical Corp (BVX)

Item 1.

Security and Issuer

The title and class of equity
securities to which this statement relates is Common Stock, par value $.001 per share.

The name and address of
the principal executive offices of the issuer is

Bovie Medical Corporation

4 Manhattanville Road,
Suite 106, Purchase NY 10577

Item 2.

Identity and Background

The identify and background
of the persons filing this statement is as follows:

Great Point Partners LLC (“Great
Point”) is a Delaware limited liability company, with its principal offices at 165 Mason Street, 3^rd Floor, Greenwich,
CT 06830.

Dr. Jeffrey R. Jay (“Dr.
Jay”) is an individual with a business address at 165 Mason Street, 3^rd Floor, Greenwich, CT 06830. Dr. Jay is
a citizen of the United States and senior managing member of Great Point.

Mr. David Kroin (“Mr.
Kroin”) is an individual with a business address at 165 Mason Street, 3^rd Floor, Greenwich, CT 06830. Mr. Kroin
is a citizen of the United States and special managing member of Great Point.

None of the Reporting Persons
was during the last five years, convicted of a criminal proceeding (excluding traffic violations or similar misdemeanors).

None of the Reporting Persons
was during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and
as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3.

Source and Amount of Funds or Other Consideration

Biomedical Value Fund, L.P.
(“BMVF”) used its own funds to purchase 1,270,255 shares of Common Stock (“BMVF Shares”) and Series A 6%
preferred stock convertible into 1,866,735 shares of Common Stock (the “BMVF Preferred Shares”).

Biomedical Offshore Value Fund,
Ltd. (“BOVF”) used its own funds to purchase 710,610 shares of Common Stock (the “BOVF Shares”) and Series
A 6% preferred stock convertible into 1,044,295 shares of Common Stock (the “BOVF Preferred Shares”.

Biomedical Institutional Value
Fund, L.P. (“BIVF”) used its own funds to purchase 326,669 shares of Common Stock (the “BIVF Shares”) and
Series A 6% preferred stock convertible into 480,065 shares of Common Stock (the “BIVF Preferred Shares”).